Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04156750 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3556050 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT04156750 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 34 participants.
The verdict
NCT04156750, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn more about the safety of LY3556050 after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3556050 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3556050 or placebo and will remain in the study for up to 31 days.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Iohexol
- DRUG LY3556050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-11-20 |
| Est. Completion | 2020-08-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04156750
The ClinicalTrials.gov registry entry for NCT04156750 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04156750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04156750 about?
NCT04156750 is a clinical study titled "A Study of LY3556050 in Healthy Participants". The main purpose of this study is to learn more about the safety of LY3556050 after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3556050 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive m...
What is the current status of trial NCT04156750?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2019-11-20. Estimated completion is 2020-08-03.
What interventions are being tested in trial NCT04156750?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Iohexol (DRUG), LY3556050 (DRUG).
Who is sponsoring clinical trial NCT04156750?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.